20
Participants
Start Date
June 13, 2022
Primary Completion Date
March 4, 2024
Study Completion Date
March 4, 2024
YH003
YH003 will be administered intravenously over 30 minutes every 21-day cycle.
Pembrolizumab
Pembrolizumab will be administered intravenously over 30 minutes every 21-day cycle.
albumin paclitaxel
Albumin paclitaxel will be administered intravenously over 30 minutes every 21-day cycle.
Sun Yat-sen University Cancer Center, Guangzhou
Cancer Hospital of Fujian, Fuzhou
Cancer Hospital of Zhenzhou, Zhengzhou
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan
Hunan Cancer Hospital, Changsha
The First Hospital of Jilin University, Jilin
The First affiliated Hospital of Dalian Medical University, Dalian
Nanjing Drum Tower Hospital, Nanjing
West China Hospital of Sichuan University, Chengdu
Tianjin Medical University Cancer Institute and Hospital, Tianjin
Yunnan Cancer Hospital, Kunming
Cancer Hospital of The University of Chinese Academy of Sciences, Hangzhou
Eucure (Beijing) Biopharma Co., Ltd
INDUSTRY